Zacks: Brokerages Expect Heron Therapeutics, Inc. (NASDAQ:HRTX) to Announce -$0.45 EPS

Wall Street brokerages expect that Heron Therapeutics, Inc. (NASDAQ:HRTXGet Rating) will post earnings per share (EPS) of ($0.45) for the current quarter, according to Zacks. Three analysts have provided estimates for Heron Therapeutics’ earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.30). Heron Therapeutics posted earnings of ($0.58) per share in the same quarter last year, which would suggest a positive year over year growth rate of 22.4%. The firm is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Heron Therapeutics will report full-year earnings of ($1.59) per share for the current financial year, with EPS estimates ranging from ($2.18) to ($0.82). For the next year, analysts expect that the company will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.20) to ($0.40). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTXGet Rating) last posted its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. Heron Therapeutics had a negative return on equity of 159.70% and a negative net margin of 255.58%. The business had revenue of $20.66 million for the quarter, compared to the consensus estimate of $25.77 million. During the same quarter in the prior year, the company earned ($0.68) EPS. The business’s revenue was up .2% compared to the same quarter last year.

A number of equities research analysts recently weighed in on HRTX shares. Zacks Investment Research downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, February 9th. StockNews.com started coverage on Heron Therapeutics in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Cowen dropped their price objective on Heron Therapeutics from $31.00 to $13.00 in a research report on Tuesday, March 1st. Cantor Fitzgerald dropped their price objective on Heron Therapeutics from $26.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 1st. Finally, Needham & Company LLC dropped their price objective on Heron Therapeutics from $24.00 to $16.00 in a research report on Tuesday, March 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $18.46.

Institutional investors have recently added to or reduced their stakes in the business. Zullo Investment Group Inc. purchased a new stake in Heron Therapeutics in the fourth quarter valued at about $30,000. Dark Forest Capital Management LP raised its stake in Heron Therapeutics by 3,258.7% in the third quarter. Dark Forest Capital Management LP now owns 3,090 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 2,998 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Heron Therapeutics in the third quarter valued at about $37,000. Russell Investments Group Ltd. purchased a new stake in Heron Therapeutics in the fourth quarter valued at about $39,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Heron Therapeutics in the third quarter valued at about $73,000.

HRTX opened at $5.87 on Friday. Heron Therapeutics has a 12-month low of $4.58 and a 12-month high of $18.99. The business’s fifty day simple moving average is $6.33 and its 200-day simple moving average is $8.55. The company has a market capitalization of $599.57 million, a price-to-earnings ratio of -2.61 and a beta of 1.32. The company has a current ratio of 3.58, a quick ratio of 2.90 and a debt-to-equity ratio of 1.92.

About Heron Therapeutics (Get Rating)

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Featured Articles

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.